VANDA PHARMACEUTICALS INC. Pre-Tax Income
VANDA PHARMACEUTICALS INC. (VNDA) reported Pre-Tax Income of -$62.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$62.38M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$48.42M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$38.00M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$28.39M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$138.65M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$22.92M, a 461.59% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $6.34M, a 43.90% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $11.30M, a 73.33% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$62.38M 10-Q · filed 2026-08-06 | -$110.81M 10-Q · filed 2026-08-06 | -$148.81M derived: sum of 3 quarters · filed 2026-08-06 | -$177.20M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$48.42M 10-Q · filed 2026-05-07 | -$86.43M derived: sum of 2 quarters · filed 2026-05-07 | -$114.82M derived: sum of 3 quarters · filed 2026-05-07 | -$149.70M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$66.39M derived: sum of 2 quarters · filed 2026-02-12 | -$101.28M derived: sum of 3 quarters · filed 2026-08-06 | -$138.65M 10-K · filed 2026-02-12 | ||
| 2025-09-30 | -$28.39M 10-Q · filed 2025-10-30 | -$63.28M derived: sum of 2 quarters · filed 2026-08-06 | -$100.64M 10-Q · filed 2025-10-30 | -$107.14M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$34.89M 10-Q · filed 2026-08-06 | -$72.25M 10-Q · filed 2026-08-06 | -$78.75M derived: sum of 3 quarters · filed 2026-08-06 | -$85.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$37.37M 10-Q · filed 2026-05-07 | -$43.87M derived: sum of 2 quarters · filed 2026-05-07 | -$50.11M derived: sum of 3 quarters · filed 2026-05-07 | -$55.63M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$12.74M derived: sum of 2 quarters · filed 2026-02-12 | -$18.26M derived: sum of 3 quarters · filed 2026-02-12 | -$22.92M 10-K · filed 2026-02-12 | ||
| 2024-09-30 | -$6.24M 10-Q · filed 2025-10-30 | -$11.76M derived: sum of 2 quarters · filed 2025-10-30 | -$16.42M 10-Q · filed 2025-10-30 | -$18.09M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-06-30 | -$5.52M 10-Q · filed 2025-07-31 | -$10.18M 10-Q · filed 2025-07-31 | -$11.84M derived: sum of 3 quarters · filed 2026-02-12 | -$11.96M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-03-31 | -$4.66M 10-Q · filed 2025-05-08 | -$6.33M derived: sum of 2 quarters · filed 2026-02-12 | -$6.45M derived: sum of 3 quarters · filed 2026-02-12 | -$3.85M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2023-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$1.78M derived: sum of 2 quarters · filed 2026-02-12 | $811.00K derived: sum of 3 quarters · filed 2026-02-12 | $6.34M 10-K · filed 2026-02-12 | ||
| 2023-09-30 | -$120.00K 10-Q · filed 2024-11-07 | $2.47M derived: sum of 2 quarters · filed 2024-11-07 | $8.00M 10-Q · filed 2024-11-07 | $17.61M derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2023-06-30 | $2.59M 10-Q · filed 2024-08-01 | $8.12M 10-Q · filed 2024-08-01 | $17.73M derived: sum of 3 quarters · filed 2025-02-14 | $23.19M derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2023-03-31 | $5.53M 10-Q · filed 2024-05-09 | $15.14M derived: sum of 2 quarters · filed 2025-02-14 | $20.60M derived: sum of 3 quarters · filed 2025-02-14 | $24.39M derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2022-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $15.07M derived: sum of 2 quarters · filed 2025-02-14 | $18.86M derived: sum of 3 quarters · filed 2025-02-14 | $11.30M 10-K · filed 2025-02-14 | ||
| 2022-09-30 | $5.46M 10-Q · filed 2023-11-09 | $9.25M derived: sum of 2 quarters · filed 2023-11-09 | $1.69M 10-Q · filed 2023-11-09 | $10.30M derived: sum of 4 quarters · filed 2024-02-08 | ||
| 2022-06-30 | $3.79M 10-Q · filed 2023-07-28 | -$3.77M 10-Q · filed 2023-07-28 | $4.84M derived: sum of 3 quarters · filed 2024-02-08 | $15.56M derived: sum of 4 quarters · filed 2024-02-08 | ||
| 2022-03-31 | -$7.56M 10-Q · filed 2023-05-03 | $1.05M derived: sum of 2 quarters · filed 2024-02-08 | $11.77M derived: sum of 3 quarters · filed 2024-02-08 | $24.37M derived: sum of 4 quarters · filed 2024-02-08 | ||
| 2021-12-31 | $8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $19.33M derived: sum of 2 quarters · filed 2024-02-08 | $31.94M derived: sum of 3 quarters · filed 2024-02-08 | $42.36M 10-K · filed 2024-02-08 | ||
| 2021-09-30 | $10.72M 10-Q · filed 2022-11-03 | $23.33M derived: sum of 2 quarters · filed 2022-11-03 | $33.75M 10-Q · filed 2022-11-03 | $44.68M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-06-30 | $12.60M 10-Q · filed 2022-08-04 | $23.03M 10-Q · filed 2022-08-04 | $33.96M derived: sum of 3 quarters · filed 2023-02-09 | $42.36M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-03-31 | $10.43M 10-Q · filed 2022-05-06 | $21.35M derived: sum of 2 quarters · filed 2023-02-09 | $29.75M derived: sum of 3 quarters · filed 2023-02-09 | |||
| 2020-12-31 | $10.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $19.32M derived: sum of 2 quarters · filed 2023-02-09 | $31.66M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | $8.40M 10-Q · filed 2021-11-04 | $20.73M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $29.03M 10-K · filed 2022-02-24 | |||||
| 2014-06-30 | -$21.57M 10-Q · filed 2014-08-08 | -$48.11M 10-Q · filed 2014-08-08 | -$55.73M derived: sum of 3 quarters · filed 2014-08-08 | -$61.11M derived: sum of 4 quarters · filed 2014-08-08 | ||
| 2014-03-31 | -$26.53M 10-Q · filed 2014-05-08 | -$34.16M derived: sum of 2 quarters · filed 2014-05-08 | -$39.54M derived: sum of 3 quarters · filed 2014-05-08 | -$42.92M derived: sum of 4 quarters · filed 2014-08-08 | ||
| 2013-12-31 | -$7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$13.00M derived: sum of 2 quarters · filed 2014-02-25 | -$16.39M derived: sum of 3 quarters · filed 2014-08-08 | -$20.25M 10-K · filed 2014-02-25 | ||
| 2013-09-30 | -$5.38M 10-Q · filed 2013-11-08 | -$8.76M derived: sum of 2 quarters · filed 2014-08-08 | -$12.63M 10-Q · filed 2013-11-08 | -$19.65M derived: sum of 4 quarters · filed 2014-08-08 | ||
| 2013-06-30 | -$3.38M 10-Q · filed 2014-08-08 | -$3.08M 10-Q · filed 2013-07-31 | -$7.90M 10-Q · filed 2014-08-08 | -$7.25M 10-Q · filed 2013-07-31 | -$14.27M derived: sum of 3 quarters · filed 2014-08-08 | -$19.60M derived: sum of 4 quarters · filed 2014-08-08 |
| 2013-03-31 | -$4.52M 10-Q · filed 2014-05-08 | -$4.17M 10-Q · filed 2013-05-10 | -$10.89M derived: sum of 2 quarters · filed 2014-05-08 | -$16.21M derived: sum of 3 quarters · filed 2014-05-08 | -$24.22M derived: sum of 4 quarters · filed 2014-05-08 | |
| 2012-12-31 | -$6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$11.70M derived: sum of 2 quarters · filed 2014-02-25 | -$19.70M derived: sum of 3 quarters · filed 2014-02-25 | -$27.66M 10-K · filed 2014-02-25 | ||
| 2012-09-30 | -$5.33M 10-Q · filed 2013-11-08 | -$13.33M derived: sum of 2 quarters · filed 2013-11-08 | -$21.30M 10-Q · filed 2013-11-08 | -$27.10M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | -$8.01M 10-Q · filed 2013-07-31 | -$15.97M 10-Q · filed 2013-07-31 | -$21.78M derived: sum of 3 quarters · filed 2014-02-25 | -$24.96M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-03-31 | -$7.96M 10-Q · filed 2013-05-10 | -$13.77M derived: sum of 2 quarters · filed 2014-02-25 | -$16.96M derived: sum of 3 quarters · filed 2014-02-25 | |||
| 2011-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$9.00M derived: sum of 2 quarters · filed 2014-02-25 | -$10.25M 10-K · filed 2014-02-25 | |||
| 2011-09-30 | -$3.19M 10-Q · filed 2012-11-08 | -$4.44M 10-Q · filed 2012-11-08 | ||||
| 2010-12-31 | $9.27M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |